Document is current
Any future updates will be listed below
-
Authors
Bonagas, Nadilly https://orcid.org/0000-0001-7336-4065
Gustafsson, Nina M. S.
Henriksson, Martin
Marttila, Petra https://orcid.org/0000-0002-0115-8067
Gustafsson, Robert https://orcid.org/0000-0002-4854-5531
Wiita, Elisée
Borhade, Sanjay
Green, Alanna C.
Vallin, Karl S. A.
Sarno, Antonio
Svensson, Richard
Göktürk, Camilla
Pham, Therese
Jemth, Ann-Sofie https://orcid.org/0000-0002-7550-1833
Loseva, Olga
Cookson, Victoria https://orcid.org/0000-0003-3089-4837
Kiweler, Nicole https://orcid.org/0000-0001-7493-703X
Sandberg, Lars
Rasti, Azita
Unterlass, Judith E.
Haraldsson, Martin
Andersson, Yasmin
Scaletti, Emma R.
Bengtsson, Christoffer
Paulin, Cynthia B. J.
Sanjiv, Kumar
Abdurakhmanov, Eldar
Pudelko, Linda
Kunz, Ben
Desroses, Matthieu
Iliev, Petar
Färnegårdh, Katarina
Krämer, Andreas https://orcid.org/0000-0003-3294-2660
Garg, Neeraj
Michel, Maurice
Häggblad, Sara
Jarvius, Malin
Kalderén, Christina
Jensen, Amanda Bögedahl
Almlöf, Ingrid
Karsten, Stella https://orcid.org/0000-0001-6191-4314
Zhang, Si Min
Häggblad, Maria
Eriksson, Anders
Liu, Jianping https://orcid.org/0000-0002-7336-3895
Glinghammar, Björn
Nekhotiaeva, Natalia
Klingegård, Fredrik
Koolmeister, Tobias
Martens, Ulf
Llona-Minguez, Sabin
Moulson, Ruth
Nordström, Helena
Parrow, Vendela
Dahllund, Leif
Sjöberg, Birger
Vargas, Irene L.
Vo, Duy Duc
Wannberg, Johan https://orcid.org/0000-0001-5494-0848
Knapp, Stefan https://orcid.org/0000-0001-5995-6494
Krokan, Hans E.
Arvidsson, Per I. https://orcid.org/0000-0002-9453-6812
Scobie, Martin
Meiser, Johannes
Stenmark, Pål https://orcid.org/0000-0003-4777-3417
Berglund, Ulrika Warpman
Homan, Evert J.
Helleday, Thomas https://orcid.org/0000-0002-7384-092X
- License Information
-
More Information
Article History
Received: 12 January 2021
Accepted: 10 January 2022
First Online: 28 February 2022
Competing interests
: C.B., S.B., M. Häggblad, T.H., M. Henriksson, E.H., C.P., L.S., M.S., P.S. and K.V. are named inventors on patent application PCT/EP2019/059919. MTHFD2 inhibitors are developed toward the clinic by the company One-Carbon Therapeutics AB, currently owned by The Helleday Foundation (THF), a not-for-profit charitable foundation. T.H. and U.W.B. are members of the board of THF. The remaining authors declare no competing interests.
